BioLargo Awarded Multiple Canadian Research Grants Excitement Builds for Its AOS Filter – Financial Support Expands

SANTA ANA, CA / JULY 28, 2015 / BioLargo, Inc. (BLGO) announced today that it had been awarded eight Canadian research grants from provincial and federal funding agencies thus far. In addition, the company has more than $1,000,000 in additional grants or financial aid in various stages of application, refinement and/or approvals. The projects underway total $168,500 supporting the continued development and commercial refinement of its AOS Filter at its dedicated research lab located within the University of Alberta research center at Agri-Food Discovery Place. Additional projects will be announced as they come to finalization and are expected in the near future.

Researchers call BioLargo’s AOS Filter results “unprecedented.” The AOS Filter combines iodine, water filter materials and electrolysis within a water filter device, generating extremely high oxidation potential in order to eliminate, soluble organic contaminants like acids, solvents, sulfurs, oil and gas by-products, and pharmaceutical by-products which are commonly found in all sorts of contaminated water. It also achieves extremely high rates of disinfection to eliminate infectious biological pathogens like Salmonella, Listeria and E.coli.

“We are extremely thankful for the expanding financial support from various federal, provincial and industry stakeholders. Interest in our technology is expanding in both Canada and internationally as the word gets out about its high levels of performance and cost-savings capabilities. We believe our AOS Filter is the lowest cost, highest impact clean-water-technology to come to market in recent history. All of these developments also expand our access to highly qualified researchers to advance the technical data and refinement as we prepare for commercialization.” said Dennis Calvert, BioLargo’s president. He added, “All of our grants are applied for through our Canadian subsidiary BioLargo Water, Inc., led by Richard Smith Ph.D., and typically support specific research activities, a particular Ph.D. researcher, university researcher, or doctorial candidate. None of the funds support general or administrative expenses unrelated to our research and development activities.We look forward to expanding these efforts as we expand our capital resources and begin to identify strategic partners to help bring the AOS Filter to market.”

About BioLargo, Inc.

BioLargo, Inc. (BLGO) makes life better by delivering technology-based products that help solve some of the world’s most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. The subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies, It is the winner of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil industry. BioLargo also owns a 50% interest in the Isan System, which was honored with a “Top 50 Water Company for the 21st Century” award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature’s Best Solution(R) and Deodorall(R) brands. (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2015.

Safe Harbor Statement

The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K for the year ended December 31, 2014.